Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.
Berger NA, Besson VC, Boulares AH, Bürkle A, Chiarugi A, Clark RS, Curtin NJ, Cuzzocrea S, Dawson TM, Dawson VL, Haskó G, Liaudet L, Moroni F, Pacher P, Radermacher P, Salzman AL, Snyder SH, Soriano FG, Strosznajder RP, Sümegi B, Swanson RA, Szabo C.
Berger NA, et al. Among authors: soriano fg.
Br J Pharmacol. 2018 Jan;175(2):192-222. doi: 10.1111/bph.13748. Epub 2017 Mar 26.
Br J Pharmacol. 2018.
PMID: 28213892
Free PMC article.
Review.